Citius Pharmaceuticals Inc logo

Citius Pharmaceuticals Inc(CTXR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.52
11/17/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CTXR

11/17/2026: CTXR (1-star) is currently NOT-A-BUY. Pass it for now.

Citius Pharmaceuticals is a micro-cap biopharmaceutical company transitioning into a commercial-stage enterprise, anchored by the recent launch of its FDA-approved lymphoma therapy, LYMPHIR. The company's primary strengths include high gross margins on initial product sales and a promising late-stage critical care pipeline. Its main growth opportunity centers on accelerating institutional adoption across medical centers to drive recurring revenue. However, key risks include persistent net losses, high cash burn, and intense competition from major pharmaceutical entities. The stock suits risk-tolerant growth investors willing to monitor commercial execution milestones and cash runway developments closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveThe recent commercialization of LYMPHIR provides tangible top-line revenue growth potential in specialty oncology.
Momentum investorMixed fitMomentum is conditional on positive technical upturn signals and accelerating quarterly institutional adoption metrics.
Value investorWeak fitThe company remains unprofitable with high cash burn, rendering traditional value metrics unsupportive.
Dividend investorWeak fitCitius pays no dividend and retains all capital for clinical and commercial expansion.
Low-risk investorWeak fitHigh share price volatility and micro-cap biotechnology risks expose investors to substantial capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap biotechnology stocks experience sharp price swings based on clinical updates and quarterly sales metrics.
Valuation riskMedium / highValuation depends heavily on speculative future commercial success rather than current earnings or book value.
Competition risk (large pharmaceutical oncology competition)HighWell-capitalized competitors can outspend smaller firms in marketing and clinical development.
Business qualityMediumTransitioning to a commercial-stage enterprise improves structural quality, but sustained profitability remains unproven.
Dividend incomeLow / noneNo dividend is distributed to shareholders.
Execution riskHighThe investment thesis relies heavily on successfully scaling the commercial adoption of LYMPHIR across hospital networks.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.17M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 263.7K shares
Beta 1.04
52 Weeks Range 0.37 - 1.54
Updated Date 11/17/2026
52 Weeks Range 0.37 - 1.54
Updated Date 11/17/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.75

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
62.3%
Active BUY / eligible
66 / 106
30-Day BUY Count Change
+23
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -57.23%
Avg. Invested days 12
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/17/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CTXR receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
CTXR has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and moderate ownership. In FY2025 versus FY2024, moderate earnings growth (+4.4%) is partially offset by soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
CTXR's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is CTXR's strongest growth driver at +5.8% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while revenue growth (+0.0%, slightly negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.6% (soft) and 98.2% of outstanding shares are publicly tradable (strong). Insider ownership of 1.80% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Geode Capital Management, LLC 0.79%
Vanguard Capital Management, LLC 0.72%
Miller Financial Services LLC 0.47%
Citadel Advisors Llc 0.46%
Jane Street Group LLC 0.45%

Unit Economics (Per $1K Revenue)

★★★★★
CTXR generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 3.23%

Quantitative Style Profile

★★★★★
CTXR has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology Therapeutics (LYMPHIR)Commercial sales of LYMPHIR through a nationwide network of pharmaceutical wholesalers and specialty distributors to medical institutions.Revenue generation is in its early stages following the late 2025 product launch, with performance tied closely to institutional ordering rates.

Valuation

Trailing PE -
Forward PE 0.32
Enterprise Value 4.86M
Price to Sales(TTM) 1.99
Enterprise Value 4.86M
Price to Sales(TTM) 1.99
Enterprise Value to Revenue 0.69
Enterprise Value to EBITDA -2.74
Shares Outstanding 27.45M
Shares Floating 26.96M
Shares Outstanding 27.45M
Shares Floating 26.96M
Percent Insiders 1.8
Percent Institutions 4.63

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.